DAVID S. COOPER, M.D.; GILBERT H. DANIELS, M.D.; E. CHESTER RIDGEWAY, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In a recent article, we retrospectively reviewed 14 cases of antithyroid-drug-related agranulocytosis (1) and reported that the risk of agranulocytosis from methimazole increased with patient age and drug dose (1). Since then, we have heard our results interpreted by others to mean that methimazole in daily doses of 30 mg or less does not cause agranulocytosis. This was clearly not our intention. One 45-year-old patient in our series developed agranulocytosis while taking 30 mg/d, and we have recently seen a 75-year-old patient develop agranulocytosis on this dose. Other examples of agranulocytosis due to methimazole at doses of
COOPER DS, DANIELS GH, RIDGEWAY EC. Agranulocytosis and Dose of Methimazole. Ann Intern Med. 1984;101:283. doi: https://doi.org/10.7326/0003-4819-101-2-283_2
Download citation file:
Published: Ann Intern Med. 1984;101(2):283.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use